ANTISENSE RNA-THERAPEUTICS IN MYOTONIC DYSTROPHY - Banco de Patentes
Banco de patentes
Comité Tech Transfer. Webinar: TESTIMONIALS “De la investigación al emprendimiento”
Destinado: Comunidad investigadora. El contexto actual derivado de la situación pandémica obliga, más si cabe, a aunar esfuerzos para avanzar en la sociedad y la economía del conocimiento. El...
Premiadas dos tecnologías del Banco de Patentes, se presentarán en Bio Boston
Dos tecnologías del Banco de Patentes, Sistema de Sellado Epidural y Antisense RNA-therapeutics in Myotonic Dystrophy, entre las ganadoras del Programa de Aceleración Comercial Internacional FIPSE...
Back ANTISENSE RNA-THERAPEUTICS IN MYOTONIC DYSTROPHY
ANTISENSE RNA-THERAPEUTICS IN MYOTONIC DYSTROPHY
Myotonic Dystrophy (DM, overall prevalence of 1/8000) is a highly disabling multisystemic disease with symptoms involving the nervous system, the heart, and the skeletal musculature. In its most common form, onset of symptoms occurs during adolescence and affected individuals have a significantly shortened lifespan of 48-55 years. Currently, DM is an unmet medical need. Researchers from INCLIVA has discovered that the inhibition of a microRNAs by antisense molecules can be therapeutic for the treatment of DM. The project is highly translational and our broad experience, preliminary data, collaboration with leading international researchers in DM1, and the interest by biotech companies, offer additional guaranties of success
INDUSTRIAL PROPERTY RIGHTS
A European patent application has been filed
related to this technology.
FURTHER INFORMATION
Quality of Life: Health Promotion and Efficient Health
CONTACT:
INCLIVA Innovation Unit
uai@incliva.es